Xvivo Perfusion AB XVIVO

GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval for additional patient enrollment in the Continued ...

Xvivo Perfusion AB (XVIPF) reports robust sales growth and a stable cash position, while navigating challenges in service segment and regulatory approvals.

GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Second quarter 2026 (Apr-Jun) Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth of 34 percent in SEK. Organic growth was ...

GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The presentation will be held in English Time: Tuesday ...

As European markets grapple with economic uncertainties and geopolitical developments, the pan-European STOXX Europe 600 Index recently experienced a modest decline of 0.53% in local currency terms. Amid this backdrop, small-cap stocks are drawing attention for their potential to offer unique opportunities, particularly when insider activity suggests confidence in a company's prospects. In exploring undervalued small caps with notable insider action, investors often look for companies that...

GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of a regulatory derogation for XVIVO's heart technology ...

GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV): The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB (publ) ("XVIVO Perfusion" or the "Company") ...

Xvivo Perfusion AB (XVIPF) reports impressive 23% organic top-line growth and maintains positive cash flow for the second consecutive quarter, despite regulatory challenges.

GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT Annual Meeting in Toronto. This prospective, ...